# Mozart Therapeutics

**Canonical:** https://apis.io/providers/mozart-therapeutics/  
**Website:** https://www.mozart-tx.com/  
**APIs profiled:** 0

Mozart Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company in Seattle, Washington, founded in 2020 to develop disease-modifying therapies for autoimmune and inflammatory disease. Its platform is built on the regulatory CD8 T cell (CD8 Treg) network — an upstream immune checkpoint that normally recognizes and eliminates the pathogenic immune cells that attack healthy tissue, and that becomes dysfunctional in autoimmune disease when inhibitory killer immunoglobulin-like receptors (KIR) block CD8 Treg activation. Rather than suppressing downstream inflammation, Mozart engineers bispecific CD8 Treg modulators intended to restore that checkpoint and re-establish long-term immune balance. Its pipeline comprises MTX-101, a KIR x CD8 bispecific antibody in Phase 1b study for type 1 diabetes, and MTX-201, a KIR x ICOS bispecific in preclinical development for inflammatory bowel disease. The company launched with a $55M Series A led by ARCH Venture Partners and Sofinnova Partners with participation from Eli Lilly, MRL Ventures Fund, Leaps by Bayer, Altitude Life Science Ventures and Alexandria Venture Investments, and later added a $25M extension including Pfizer Ventures, AbbVie Ventures, Ono Venture Investment and UPMC Enterprises. Mozart Therapeutics sells therapeutics, not software: it runs no developer program, publishes no API, SDK or machine-readable specification, and maintains no public source-code organization.

## Kin Score — 3.3 / 100 (minimal)

Scored 2026-09-02 under rubric 0.18.0. Trend: flat (+0.0 from 3.3).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 7.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Mozart Therapeutics Domain Security** — TLSv1.3

## Tags

Company, Biotechnology, Pharmaceuticals, Immunology, Autoimmune Disease, Drug Discovery, Life Sciences, Clinical Trials, Bispecific Antibodies, Research

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/mozart-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.